Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy
Status:
Unknown status
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Somatostatine induces a dose-dependent reduction of postprandial plasma cholecystokinin (CCK)
secretion with a concomitant inhibition of postprandial gallbladder contraction, abolishing
almost completely bile salts output from the gallbladder. Somatostatine is also known to
decrease acid production with significant increase of intragastric pH. In this way,
somatostatine could influence acid as well as non-acid reflux by decreasing gallbladder
emptying and decreasing acid secretion.
Purpose of the study is to evaluate the efficacy of lanreotide autogel 120 mg on symptoms and
endoscopic lesions in patients with an endoscopic gastrointestinal reflux esophagitis that
cannot be controlled with classic therapy.